AstraZeneca News On Cancer And Asthma Raises New Questions For Investors [Yahoo! Finance]
Johnson & Johnson (JNJ)
Last johnson & johnson earnings: 4/14 06:31 am
Check Earnings Report
US:NYSE Investor Relations:
jnj.com
Company Research
Source: Yahoo! Finance
Get insights on thousands of stocks from the global community of over 7 million individual investors at Simply Wall St. AstraZeneca (LSE:AZN) received US FDA approval for CALQUENCE as an all oral, fixed duration therapy for chronic lymphocytic leukemia and small lymphocytic lymphoma. The European Medicines Agency validated ENHERTU for use in early stage HER2 positive breast cancer, supported by phase 3 trial data. Full phase III results for BREZTRI in asthma were published in The Lancet Respiratory Medicine, adding fresh clinical data in respiratory care. For investors tracking LSE:AZN, these announcements cluster around two core franchises: oncology and respiratory disease. CALQUENCE and ENHERTU sit in cancer segments where targeted therapies and earlier line treatments have been a key focus, while BREZTRI extends AstraZeneca's long running presence in chronic respiratory conditions such as asthma. In the near term, you may want to watch how physicians, regulators, and tre
Show less
Read more
Impact Snapshot
Event Time:
JNJ
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
JNJ alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
JNJ alerts
High impacting Johnson & Johnson news events
Weekly update
A roundup of the hottest topics
JNJ
News
- Johnson And Johnson Faces Fresh Talc Verdict As Pipeline Story Evolves [Yahoo! Finance]Yahoo! Finance
- Early study results from Johnson & Johnson show promising antitumor activity with combination of pasritamig and docetaxel in advanced prostate cancer [Yahoo! Finance]Yahoo! Finance
- Early study results from Johnson & Johnson show promising antitumor activity with combination of pasritamig and docetaxel in advanced prostate cancerPR Newswire
- Are You Looking for a High-Growth Dividend Stock? [Yahoo! Finance]Yahoo! Finance
- Juvenescence successfully completes Phase 1 clinical trial of PAI-1 inhibitor and strengthens clinical development leadership [Yahoo! Finance]Yahoo! Finance
JNJ
Earnings
- 1/21/26 - Beat
JNJ
Sec Filings
- 2/23/26 - Form 4
- 2/20/26 - Form 144
- 2/18/26 - Form 4
- JNJ's page on the SEC website